TNF and connective tissue disorder: In a study evaluating adverse reactions following the use of TNF-α inhibitors in VigiAccess of the World Health Organization (WHO), the most reported adverse events of these drugs were infections and infestations (23.0%), musculoskeletal and connective tissue disorders (28.6%), gastrointestinal disorders (15.3%), skin and subcutaneous tissue disorders (13.5%), and nervous system disorders (11.0%) [89].